<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184297</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0094</org_study_id>
    <nct_id>NCT04184297</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy</brief_title>
  <official_title>Effectiveness and Safety of Maintenance Treatment With Combination of Tiotropium and Olodaterol in Comparison to Maintenance Treatment With a Combination of Inhaled Corticosteroids, Long-acting β2 Agonists and Long-acting Muscarinic Antagonists in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo)
      (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this
      varies across COPD sub populations defined by exacerbation risk
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first COPD exacerbation occurrence of a hospitalization for COPD (severe exacerbation) or ED visit</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First hospitalization for community-acquired pneumonia (serious pneumonia) based on ICD-9-CM diagnoses</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4000</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjets initiated with LABA/LAMA/ICS</arm_group_label>
    <description>Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium and Olodaterol (Tio+Olo)</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjets initiated with LABA/LAMA/ICS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with COPD inititated with Tio+Olo in comparison to patients treated with
        ICS/LABA/LAMA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New users of Tio+Olo on the same date or of LABA, LAMA and ICS, either as a fixed-dose
             combination (LABA/LAMA/ICS) or free combination (LABA/ICS + LAMA, etc), on the same
             date between January 2013 and March 2019.

          -  Diagnosis of COPD prior to first maintenance inhaler and age ≥ 40 years at index date

        Exclusion Criteria:

          -  Less than one year of medical history information prior to the date of combined
             treatment initiation (index date)

          -  Lung cancer, interstitial lung disease, or lung transplantation at any time prior to
             the index date

          -  Asthma diagnosis within one year prior to the index date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HealthCore, Inc.</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringer-ingelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the Research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned Analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

